Neurotech International (ASX:NTI) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Neurotech International EBITDA Margin %?

Neurotech International ASX:NTI -7.14% EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Neurotech International ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neurotech International's EBITDA for the six months ended in Dec. 2025 was A$-5.44 Mil. Neurotech International's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Neurotech International's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Neurotech International  (ASX:NTI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Neurotech International EBITDA Margin % Related Terms

Neurotech International EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Neurotech International's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International EBITDA Margin % Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -3,606.31 -8,842.11 -150,783.33 -420,100.00 0.00

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196,900.00 0.00 0.00 0.00 0.00

ASX:NTI vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Neurotech International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurotech International EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurotech International's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Neurotech International's EBITDA Margin % falls into.


Neurotech International EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Neurotech International's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-13.18/0
= %

Neurotech International's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-5.438/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Neurotech International (ASX:NTI) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurotech International and its competitors. According to the industry distribution chart, Neurotech International ranks #999999 out of 944 companies in the Biotechnology industry.
Is Neurotech International's EBITDA Margin % too high?
Neurotech International's current EBITDA Margin % is 0.00%. Based on the distribution chart, Neurotech International ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neurotech International's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #999999 out of 944 companies for EBITDA Margin %. This places Neurotech International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurotech International and its competitors. Neurotech International's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (ASX:NTI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neurotech International (ASX:NTI), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.